Navigation Links
Transdel Pharmaceuticals Presents Phase 3 Study Data on Ketotransdel® at World Pain Congress in Montreal, Canada
Date:9/2/2010

related cutaneous/application site adverse events was slightly lower with TDLP-110 (1.1% vs. placebo 2.2%, respectively). There were no clinically relevant shifts from baseline in laboratory parameters (hematology, coagulation, serum chemistry, and urinalysis). The estimated systemic absorption of TDLP-110 is about 1 - 2 % of a comparable oral ketoprofen dose. In a pharmacokinetic sub-study of this Phase 3 trial minimal blood concentrations (mean Cmax 39.0 ng/mL) of ketoprofen were measured at steady-state, which is consistent with previous Phase 1/2 study findings. This Phase 3 study (TDLP-110-001) demonstrated that TDLP-110 was more effective than placebo in reducing pain of acute soft tissue injuries and was very well tolerated.

"Today's presentation of our data at the world's premier congress devoted to research and treatment of pain is a significant event for our company," stated Joachim Schupp, M.D., Chief Medical Officer at Transdel Pharmaceuticals. "We believe that study TDLP-110-001 could serve as one of two required confirmatory trials of evidence of efficacy for TDLP-110 and we plan to initiate the second trial upon sufficient funding."

To view the poster presented at the conference, please visit the Company's website at www.transdelpharma.com.

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company's innovative-patented Transdel™ cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier.  Ketotransdel®, the Company's lead pain product candidate, has completed a Phase 3 clinical trial and utilizes the Transdel™ technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug through the skin directly into the underlyi
'/>"/>

SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Transdel Pharmaceuticals Announces Management Reorganization
2. Transdel Pharmaceuticals to Webcast Presentation at 4th Annual BIOCOM Investor Conference
3. Transdel Enrolls First Patient for Ketotransdel(TM) Phase 3 Clinical Trial
4. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
5. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
6. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
7. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
8. Pfizer to Acquire FoldRx Pharmaceuticals
9. Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China
10. Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015
11. Webcast Alert: Isis Pharmaceuticals Hosts Expert Panel Conference Call to Discuss Mipomersen Data Presented at the ESC Congress 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  EP Global Communications, Inc. (Public ... recently contacted the Company about discussing EPGL,s electronic ... as Monday, August 3, 2015.  Novartis CEO ... that the coming electronic contact lens market could ... the next several years.  Novartis partnered with Google ...
(Date:7/30/2015)... PLAINFIELD, N.J., July 30, 2015 PTC Therapeutics, ... update and reported financial results for the second quarter ... progressing on many fronts across the organization.  We are ... Duchenne muscular dystrophy clinical trial ever conducted with topline ... Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "Translarna ...
(Date:7/30/2015)... 2015  Growth of the U.S. nonprescription market is ... prescription users to the OTC market. Due to an ... Rx-to-OTC switch activity over the next five years with ... new brands entering the market into existing categories. ... years (even those with low to moderate likelihood), the ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... builds on company,s suite of tests to evaluate ... a leading clinical-diagnostics and biomedical-research laboratory specializing in ... diagnostic assay designed to help physicians better understand ... The company will introduce the Pneumococcal Antibody ...
... March 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") ... it has started patient enrolment in a Phase ... in combination with paclitaxel and carboplatin in patients ... or EGFR-activated tumours. The Principal Investigator is Dr. ...
Cached Medicine Technology:IBT Laboratories to Launch New Pneumococcal Antibody Avidity Test at AAAAI Meeting, Booth 729 2Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 2
(Date:7/31/2015)... , ... July 31, 2015 , ... In the most ... U.S. District Court in the Northern District of Illinois, Androgel testosterone attorneys report that ... 20, a docket entry was made recording the minutes of the status conference, which ...
(Date:7/31/2015)... ... July 31, 2015 , ... Intellitec Solutions announced today ... of Microsoft Dynamics GP for a senior living facility in Maine. Having achieved ... living communities in 16 states. This further expansion was again a factor of ...
(Date:7/30/2015)... ... ... When responsible for the care of an aging loved one, summer vacations ... What happens if mom falls? Who will remind Dad to take his medications? What ... not taking time away from caregiving responsibilities can lead to bigger problems – caregiver ...
(Date:7/30/2015)... ... 2015 , ... On July 22nd the Bradenton Herald reported the ... for controlling the heroin outbreak. Ultimately the committee expressed lack of funding, and the ... heroin crisis in North Florida. The task force has proposed to instate counselors to ...
(Date:7/30/2015)... ... July 30, 2015 , ... The ... BioPharma, Inc. are pleased to announce that data standards for clinical research in ... on the CDISC website . These three Therapeutic Area (TA) standards were ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 3Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5
... planned spinoff later this summer , , SAN DIEGO, ... public following the planned spinoff of Cardinal Health,s clinical and ... the occasion by providing opportunities for its global employees to ... "This is an exciting day for our company and employees ...
... (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime, Chief ... on Thursday, July 30, at 5:00 p.m. ET (23:00 CET) to ... U.S. / Canada Dial-in Number: 866.272.9941, ... 45596036, Replay Dial-in Number: 888.286.8010, ...
... Women are more vulnerable during certain stages of ... News) -- Fluctuating hormone levels may explain trends ... diseases such as Parkinson,s, schizophrenia, Alzheimer,s, Tourette,s and ... level changes occur at various stages of women,s ...
... amoxicillin in kids, , WEDNESDAY, July 1 (HealthDay News) ... infections in young children increases the risk of recurrent ... the Netherlands who called for more prudent use of ... 63 percent of children given the antibiotic amoxicillin experienced ...
... safety in those who think the same way, research contends ... you believe, new research suggests that you,re likely to surround ... be friends or talking heads on television. , "Never having ... way of protecting your beliefs. It,s a little bit primitive, ...
... WOODLANDS, Texas, July 1 eCardio Diagnostics ... arrhythmia monitoring services, today announced that it has received a ... round of institutional funding since the company was founded in ... marks a milestone in the growth of eCardio," noted Larry ...
Cached Medicine News:Health News:CareFusion Launches New Brand, Establishing Itself as an Industry Leader in Helping Hospitals Improve Patient Care and Safety 2Health News:CareFusion Launches New Brand, Establishing Itself as an Industry Leader in Helping Hospitals Improve Patient Care and Safety 3Health News:BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast on Thursday, July 30 at 5:00 p.m. ET (23:00 CET) 2Health News:Hormones May Affect Neurological Disease Risk 2Health News:Antibiotics May Boost Risk for Recurrent Ear Infection 2Health News:Your Surroundings Mirror Your Beliefs 2Health News:Your Surroundings Mirror Your Beliefs 3Health News:eCardio Receives Significant Investment in Private Funding from Sequoia Capital 2
... Microalbumin Strips provide albumin, creatinine and albumin-to-creatinine ... Microalbumin product is useful to test for ... in order to detect early kidney disease. ... the urinary albumin excretion rate, is an ...
... to near-patient urinalysis. The Chemstrip ... affordable, reliable alternative to visual ... fundamental, easy-to-use features, the Chemstrip ... office lab, clinic, and hospital ...
... UA is the first hand-held urine ... valuable lab bench space. Automation of ... in results between operators and transcription ... run, corrects for ambient temperature and ...
... first outside-the-balloon, dual-wire dilatation catheter. The ... innovative new approach to dilatation. Its unique, ... wires to create expansion planes at low ... ,The FX miniRAIL RX PTCA Catheter is ...
Medicine Products: